by nobilistx | Dec 8, 2020 | Uncategorized |
As one of the few selected companies Nobilis Therapeutics had the opportunity to present its technology in front of over 100 sophisticated investors. While we didn’t win, our presentation and the Q&A session were very well received and have started a number...
by nobilistx | Oct 22, 2020 | Uncategorized |
PORTLAND, Ore., October 22, 2020 – Nobilis Therapeutics announced today the issuance of a US Patent (US Patent No: 10,792,305 B2) for a patent titled “Therapeutic immune modulation using noble gas compositions.” One of it broadest claims includes “a method of treating...
by nobilistx | Jul 22, 2020 | Uncategorized |
Nobilis Therapeutics, a biopharmaceutical company today announced that the U.S. Food & Drug Administration (FDA) has allowed it to initiate a Phase 2b clinical trial of its lead drug candidate NBTX-001 in patients with Panic Disorder. PORTLAND, ORE. (PRWEB) JULY...
by nobilistx | Jun 23, 2020 | Uncategorized |
Nobilis Therapeutics, a biopharmaceutical company focused on the advancement of innovative CNS therapies, today announced that it has filed an Investigational New Drug application (IND) with the U.S. Food & Drug Administration (FDA) to initiate a Phase 2b clinical...
by nobilistx | Jun 22, 2020 | Uncategorized |
The National Institute on Drug Abuse (NIDA), one of the components of the National Institutes of Health (NIH), announced its 5th “$100,000 for Start a SUD Startup” Challenge. The Challenge goal is to support research ideas that would further an understanding of...
by nobilistx | May 2, 2020 | Uncategorized |
PORTLAND, Ore., May 2, 2020 – Nobilis Therapeutics announced today the issuance of a Notice of Allowance (European Patent Application No: 16815312.0) for a patent titled “Therapeutic immune modulation using noble gas compositions.” “We have uncovered substantial...
